Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)
China flag China · Delayed Price · Currency is CNY
24.85
+0.10 (0.40%)
Nov 5, 2026, 3:04 PM CST

Hubei Goto Biopharm Group Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
654.98595.45532.57565.5604.4588.37
Other Revenue
10.7310.734.030.90.172.52
665.71606.18536.6566.4604.57590.89
Revenue Growth
6.30%12.97%-5.26%-6.31%2.32%26.23%
Cost of Revenue
601.27533.49435.71450.29466.77446.63
Gross Profit
64.4472.69100.89116.11137.81144.26
Selling, General & Admin
71.7465.467.2950.1642.540.58
Research & Development
63.569.8551.0838.145.1537.12
Other Operating Expenses
-8.78-14.39-6.98-3.53-0.171.53
Operating Expenses
129.14126.94115.6289.1792.3579.78
Operating Income
-64.7-54.25-14.7326.9345.4664.48
Interest Expense
-53.18-47.73-23.52-13.18-13.68-5.17
Interest & Investment Income
0.30.81.052.391.921.19
Currency Exchange Gain (Loss)
-1.61-1.611.121.052.24-0.6
Other Non Operating Income (Expenses)
-4.21-0.51-1.41-0.5-0.59-0.72
EBT Excluding Unusual Items
-123.39-103.31-37.4816.735.3559.17
Gain (Loss) on Sale of Investments
-6.11-0.27-0.35-0.01-0.18-1.05
Gain (Loss) on Sale of Assets
0.05-1.440.110.17-0.01-
Asset Writedown
11.77-3.79-10.46-2.23-0.96-0.06
Legal Settlements
----0.03-0.050.01
Other Unusual Items
2.643.592.644.534.3628.05
Pretax Income
-115.03-105.21-45.5419.1238.5186.12
Income Tax Expense
-15.05-23.49-13.88-2.17-18.05
Earnings From Continuing Operations
-99.98-81.73-31.6621.2939.5178.07
Minority Interest in Earnings
10.298.374.071.720.690.26
Net Income
-89.7-73.36-27.5923.0140.2178.33
Net Income to Common
-89.7-73.36-27.5923.0140.2178.33
Net Income Growth
----42.78%-48.67%46.99%
Shares Outstanding (Basic)
115115115115115106
Shares Outstanding (Diluted)
115115115115115106
Shares Change
1.33%-0.29%-0.05%0.13%8.77%22.87%
EPS (Basic)
-0.78-0.64-0.240.200.350.74
EPS (Diluted)
-0.78-0.64-0.240.200.350.74
EPS Growth
----42.86%-52.81%19.63%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-11.47-125.29-332.2-341.12-431.98-32.91
Free Cash Flow Per Share
-0.10-1.09-2.89-2.97-3.76-0.31
Dividend Per Share
0.0450.045-0.016-0.136
Dividend Growth
------
Gross Margin
9.68%11.99%18.80%20.50%22.79%24.41%
Operating Margin
-9.72%-8.95%-2.74%4.75%7.52%10.91%
Profit Margin
-13.47%-12.10%-5.14%4.06%6.65%13.26%
Free Cash Flow Margin
-1.72%-20.67%-61.91%-60.23%-71.45%-5.57%
EBITDA
104.9461.128.2653.469.7686.76
EBITDA Margin
15.76%10.08%5.27%9.43%11.54%14.68%
D&A For EBITDA
169.64115.3642.9826.4724.322.28
EBIT
-64.7-54.25-14.7326.9345.4664.48
EBIT Margin
-9.72%-8.95%-2.74%4.75%7.52%10.91%
Effective Tax Rate
-----9.35%
Revenue as Reported
665.71606.18536.6566.4604.57590.89